Using machine learning algorithms to review computed tomography scans and assess risk for cardiovascular disease: Retrospective analysis from the National Lung Screening Trial (NLST)

PLoS One. 2020 Aug 3;15(8):e0236021. doi: 10.1371/journal.pone.0236021. eCollection 2020.

Abstract

Background: The National Lung Screening Trial (NLST) demonstrated that annual screening with low dose CT in high-risk population was associated with reduction in lung cancer mortality. Nonetheless, the leading cause of mortality in the study was from cardiovascular diseases.

Purpose: To determine whether the used machine learning automatic algorithms assessing coronary calcium score (CCS), level of liver steatosis and emphysema percentage in the lungs are good predictors of cardiovascular disease (CVD) mortality and incidence when applied on low dose CT scans.

Materials and methods: Three fully automated machine learning algorithms were used to assess CCS, level of liver steatosis and emphysema percentage in the lung. The algorithms were used on low-dose computed tomography scans acquired from 12,332 participants in NLST.

Results: In a multivariate analysis, association between the three algorithm scores and CVD mortality have shown an OR of 1.72 (p = 0.003), 2.62 (p < 0.0001) for CCS scores of 101-400 and above 400 respectively, and an OR of 1.12 (p = 0.044) for level of liver steatosis. Similar results were shown for the incidence of CVD, OR of 1.96 (p < 0.0001), 4.94 (p < 0.0001) for CCS scores of 101-400 and above 400 respectively. Also, emphysema percentage demonstrated an OR of 0.89 (p < 0.0001). Similar results are shown for univariate analyses of the algorithms.

Conclusion: The three automated machine learning algorithms could help physicians to assess the incidence and risk of CVD mortality in this specific population. Application of these algorithms to existing LDCT scans can provide valuable health care information and assist in future research.

Publication types

  • Evaluation Study

MeSH terms

  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / mortality*
  • Cigarette Smoking / adverse effects
  • Cigarette Smoking / epidemiology
  • Clinical Trials, Phase III as Topic
  • Coronary Vessels / diagnostic imaging
  • Early Detection of Cancer / methods
  • Emphysema / diagnosis
  • Emphysema / epidemiology
  • Emphysema / etiology
  • Fatty Liver / diagnosis
  • Fatty Liver / epidemiology
  • Female
  • Humans
  • Liver / diagnostic imaging
  • Lung / diagnostic imaging
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / etiology
  • Lung Neoplasms / mortality
  • Machine Learning*
  • Male
  • Mass Screening / methods
  • Middle Aged
  • National Cancer Institute (U.S.)
  • Radiographic Image Interpretation, Computer-Assisted / methods*
  • Randomized Controlled Trials as Topic
  • Retrospective Studies
  • Risk Assessment / methods
  • Risk Factors
  • Tomography, X-Ray Computed*
  • United States / epidemiology

Grants and funding

EE, RS, DC, OBA, and MA are employees of Zebra Medical Vision and have stock options in the company. The funder provided support in the form of salaries for authors EE, RS, DC, OBA, MA and LD, but did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.